Canaccord Genuity Group Lowers Tenaya Therapeutics Price Target to 17.00
TNYA Stock | USD 2.75 0.83 23.18% |
About 70% of Tenaya Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Tenaya Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Tenaya Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Tenaya Therapeutics stock news signals to limit their universe of possible portfolio assets.
Tenaya |
Tenaya Therapeutics had its target price lowered by Canaccord Genuity Group from 18.00 to 17.00 in a research report report published on Friday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. Other equities analysts have also recently issued reports about the company. Lifesci Capital reissued an
Read at thelincolnianonline.com
Tenaya Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Tenaya Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tenaya Therapeutics Fundamental Analysis
We analyze Tenaya Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tenaya Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tenaya Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Tenaya Therapeutics is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Tenaya Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tenaya Therapeutics stock to make a market-neutral strategy. Peer analysis of Tenaya Therapeutics could also be used in its relative valuation, which is a method of valuing Tenaya Therapeutics by comparing valuation metrics with similar companies.
Peers
Tenaya Therapeutics Related Equities
GOSS | Gossamer Bio | 28.17 | ||||
DRTS | Alpha Tau | 1.32 | ||||
INZY | Inozyme Pharma | 0.68 | ||||
CRVS | Corvus Pharmaceuticals | 0.37 | ||||
AKRO | Akero Therapeutics | 4.35 | ||||
BCYC | Bicycle Therapeutics | 4.65 | ||||
STOK | Stoke Therapeutics | 5.08 | ||||
BMEA | Biomea Fusion | 5.54 | ||||
OCUL | Ocular Therapeutix | 5.83 | ||||
ALXO | Alx Oncology | 5.96 | ||||
RANI | Rani Therapeutics | 6.45 | ||||
GLUE | Monte Rosa | 8.46 | ||||
VINC | Vincerx Pharma | 9.52 | ||||
IGMS | IGM Biosciences | 11.14 |
Complementary Tools for Tenaya Stock analysis
When running Tenaya Therapeutics' price analysis, check to measure Tenaya Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenaya Therapeutics is operating at the current time. Most of Tenaya Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenaya Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenaya Therapeutics' price. Additionally, you may evaluate how the addition of Tenaya Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |